<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="142c8672-a552-4d20-9226-2a92aa9773d1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use QINLOCK safely and effectively. See full prescribing information for QINLOCK.<br/>
      <br/>QINLOCK<sup>Â®</sup> (ripretinib) tablets, for oral use<br/>Initial U.S. Approval: 2020
</title>
   <effectiveTime value="20250512"/>
   <setId root="9f18e462-03dd-4296-a02a-a0577e3ee78d"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="078027928" root="1.3.6.1.4.1.519.1"/>
            <name>Deciphera Pharmaceuticals, LLC
</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="3dbb0b04-afd9-4a53-be67-d8079bcb213c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20200515"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73207-101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>QINLOCK
</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ripretinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="50" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9XW757O13D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ripretinib
</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9XW757O13D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Ripretinib</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6N003M473W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose acetate succinate 06081224 (3 MM2/S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>microcrystalline cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>crospovidone</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>silicon dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73207-101-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20200515"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73207-101-31" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20200515"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="17" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">DC1
</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200515"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213973" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20200515"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="ea753704-8940-43de-82fa-e48389a71b4c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. (<linkHtml href="#s2">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="402445a6-ed78-41ff-848e-8ad8dfcd2ef9"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage</content>: 150Â mg orally once daily with or without food. (<linkHtml href="#s4">2.1</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s4">
                     <id root="730cf32d-4405-4ae4-a074-a891004e279b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage
</title>
                     <text>
                        <paragraph>The recommended dosage of QINLOCK is 150Â mg orally once daily with or without food until disease progression or unacceptable toxicity.</paragraph>
                        <paragraph>Instruct patients to swallow tablets whole.</paragraph>
                        <paragraph>Advise patients to take QINLOCK at the same time each day.</paragraph>
                        <paragraph>Advise patients to take a missed dose if less than 8 hours have passed since the missed scheduled dose.</paragraph>
                        <paragraph>Advise patients not to take an additional dose if vomiting occurs after taking QINLOCK and to continue with their next scheduled dose.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="138b563d-e634-4c2c-8723-d4bdea299046"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Modifications for Adverse Reactions
</title>
                     <text>
                        <paragraph>The recommended dose reduction for adverse reactions is:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>QINLOCK 100 mg orally once daily.</item>
                        </list>
                        <paragraph>Permanently discontinue QINLOCK in patients who are unable to tolerate 100 mg orally once daily.</paragraph>
                        <paragraph>The recommended dosage modifications of QINLOCK for adverse reactions are provided in <linkHtml href="#t1">Table 1</linkHtml>.</paragraph>
                        <table ID="t1" width="100%">
                           <caption>Table 1: Recommended Dosage Modifications for QINLOCK for Adverse Reactions </caption>
                           <colgroup>
                              <col width="25.800%" align="left"/>
                              <col width="19.167%" align="left"/>
                              <col width="55.033%" align="left"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </th>
                                 <th styleCode="Botrule Rrule Toprule" align="left" valign="top">
                                    <content styleCode="bold">Severity</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </th>
                                 <th styleCode="Botrule Rrule Toprule" align="left" valign="top">
                                    <content styleCode="bold">QINLOCK Dosage Modifications</content>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>a</sup> Graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03).</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" rowspan="2" align="left" valign="top">Palmar-Plantar Erythrodysesthesia Syndrome (PPES) <content styleCode="italics">[seeÂ Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Grade 2</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold QINLOCK until Grade â¤1 or baseline. If recovered within 7Â days, resume QINLOCK at same dose; otherwise resume at reduced dose.</item>
                                       <item>Consider re-escalating QINLOCK if maintained at Grade â¤1 or baseline for at least 28Â days.</item>
                                       <item>If PPES recurs, withhold QINLOCK until Grade â¤1 or baseline and then resume QINLOCK at a reduced dose regardless of time to improvement.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Grade 3</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold QINLOCK for at least 7 days or until Grade â¤1 or baseline (maximum 28 days). Resume QINLOCK at a reduced dose.</item>
                                       <item>Consider re-escalating QINLOCK if maintained at Grade â¤1 or baseline for at least 28 days.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" rowspan="2" align="left" valign="top">Hypertension <content styleCode="italics">[seeÂ Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Grade 3</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>If symptomatic, withhold QINLOCK until symptoms have resolved and blood pressure is controlled.</item>
                                       <item>If blood pressure is controlled to Grade â¤1 or baseline, resume QINLOCK at the same dose; otherwise, resume QINLOCK at reduced dose.</item>
                                       <item>If Grade 3 hypertension recurs, withhold QINLOCK until symptoms have resolved and blood pressure is controlled. Resume QINLOCK at a reduced dose.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Grade 4</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Permanently discontinue QINLOCK.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Left Ventricular Systolic Dysfunction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Grade 3 or 4</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Permanently discontinue QINLOCK.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" rowspan="2" align="left" valign="top">Arthralgia or Myalgia <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s18">6.1</linkHtml>)]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Grade 2</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold QINLOCK until Grade â¤1 or baseline. If recovered within 7Â days, resume QINLOCK at same dose; otherwise resume QINLOCK at reduced dose.</item>
                                       <item>Consider re-escalating QINLOCK if maintained at Grade â¤1 or baseline for at least 28 days.</item>
                                       <item>If arthralgia or myalgia recurs, withhold QINLOCK until Grade â¤1 or baseline and then resume QINLOCK at a reduced dose regardless of time to improvement.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Grade 3</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold QINLOCK for at least 7 days or until Grade â¤1 or baseline (maximum of 28 days). Resume QINLOCK at a reduced dose.</item>
                                       <item>Consider re-escalating QINLOCK if maintained at Grade â¤1 or baseline for at least 28 days.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Other Adverse Reactions <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s18">6.1</linkHtml>)]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">Grade 3 or 4</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold QINLOCK until Grade â¤1 or baseline (maximum 28 days), and then resume QINLOCK at a reduced dose; otherwise permanently discontinue.</item>
                                       <item>Consider re-escalating QINLOCK if no recurrence of the adverse reaction for at least 28 days.</item>
                                       <item>If Grade 3 or 4 recurs, permanently discontinue QINLOCK.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="5c569b05-3b40-4930-8c8d-a5ea20038d58"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dose Modifications for Moderate CYP3A Inducers
</title>
                     <text>
                        <paragraph>Avoid concomitant use of moderate CYP3A inducers during QINLOCK treatment.</paragraph>
                        <paragraph>If a moderate CYP3A inducer cannot be avoided, increase the QINLOCK dosing frequency from the recommended dose of 150 mg once daily to 150 mg twice daily during the co-administration period. Monitor for clinical response and tolerability. If the concomitant moderate CYP3A inducer is discontinued, resume QINLOCK dosage back to 150 mg once daily 14 days after the discontinuation of the moderate CYP3A inducerÂ <content styleCode="italics">[seeÂ Drug Interactions (<linkHtml href="#s23">7.1</linkHtml>)Â andÂ Clinical Pharmacology (<linkHtml href="#s47">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>For patients concomitantly using a moderate CYP3A inducer with QINLOCK (taking QINLOCK twice daily) who missed a dose:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>If less than 4 hours have passed since the missed scheduled dose, advise the patient to take the missed dose as soon as possible and then take the next dose at the regularly scheduled time.</item>
                           <item>If more than 4 hours have passed since the missed scheduled dose, advise the patient to skip the missed dose and then take the next dose at the regularly scheduled time. <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s23">7.1</linkHtml>)]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="b40d8e16-8911-4d25-9d90-92901d59b6ca"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Tablets: 50Â mg, white to off-white, oval shaped, debossed with âDC1â on one side.
</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 50Â mg. (<linkHtml href="#s7">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="ff740019-635a-4d46-82a1-014626c71957"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>None.
</paragraph>
               </text>
               <effectiveTime value="20220927"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#s8">4</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="cb3c2f8c-b918-4ebb-90e5-6cfb6168c86c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Palmar-Plantar Erythrodysesthesia Syndrome</content>: Based on severity, withhold QINLOCK and resume at same or reduced dose. (<linkHtml href="#s5">2.2</linkHtml>, <linkHtml href="#s10">5.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">New Primary Cutaneous Malignancies</content>: Perform dermatologic evaluations when initiating QINLOCK and routinely during treatment. (<linkHtml href="#s11">5.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Hypertension</content>: Do not initiate QINLOCK in patients with uncontrolled hypertension and monitor blood pressure during treatment. Based on severity, withhold QINLOCK and then resume at same or reduced dose or permanently discontinue. (<linkHtml href="#s5">2.2</linkHtml>, <linkHtml href="#s12">5.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Cardiac Dysfunction</content>: Assess ejection fraction by echocardiogram or MUGA scan prior to initiating QINLOCK and during treatment, as clinically indicated. Permanently discontinue QINLOCK for Grade 3 or 4 left ventricular systolic dysfunction. (<linkHtml href="#s5">2.2</linkHtml>, <linkHtml href="#s13">5.4</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Risk of Impaired Wound Healing</content>: Withhold QINLOCK for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of QINLOCK after resolution of wound healing complications has not been established. (<linkHtml href="#s14">5.5</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Photosensitivity</content>: May cause photosensitivity reactions. Advise patients to limit direct ultraviolet exposure. (<linkHtml href="#s15">5.6</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#s16">5.7</linkHtml>,Â <linkHtml href="#s25">8.1</linkHtml>,Â <linkHtml href="#s31">8.3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s10">
                     <id root="0694afee-3394-46f9-95fd-2d7ecdeef614"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Palmar-Plantar Erythrodysesthesia Syndrome
</title>
                     <text>
                        <paragraph>In INVICTUS, Grade 1-2 palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 21% of the 85Â patients who received QINLOCK <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s18">6.1</linkHtml>)].</content> PPES led to dose discontinuation in 1.2%Â of patients, dose interruption in 2.4% of patients, and dose reduction in 1.2% of patients.</paragraph>
                        <paragraph>Based on severity, withhold QINLOCK and then resume at same or reduced dose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s5">2.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="2fb66458-20cc-4fd8-98dd-e85a86bfe1d9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 New Primary Cutaneous Malignancies
</title>
                     <text>
                        <paragraph>In INVICTUS, cutaneous squamous cell carcinoma (cuSCC) occurred in 4.7% of the 85 patients who received QINLOCK, with a median time to event of 4.6 months (range: 3.8 to 6 months). In the pooled safety population, cuSCC and keratoacanthoma occurred in 7% and 1.9% of patients, respectively.</paragraph>
                        <paragraph>In INVICTUS, melanoma occurred in 2.4% of the 85 of patients who received QINLOCK. In the pooled safety population, melanoma occurred in 0.9% of patients.</paragraph>
                        <paragraph>Perform dermatologic evaluations when initiating QINLOCK and routinely during treatment. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Continue QINLOCK at the same dose.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="99fbee57-af8b-4b09-bc4d-621e324a6f88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypertension
</title>
                     <text>
                        <paragraph>In INVICTUS, Grade 1-3 hypertension occurred in 14% of the 85Â patients who received QINLOCK, including Grade 3 hypertension in 7% <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s18">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Do not initiate QINLOCK in patients with uncontrolled hypertension. Adequately control blood pressure prior to initiating QINLOCK. Monitor blood pressure as clinically indicated during treatment with QINLOCK, and initiate or adjust antihypertensive therapy as appropriate. Based on severity, withhold QINLOCK and then resume at same or reduced dose or permanently discontinue <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s5">2.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="8acf8fd0-0940-4c7f-ad19-a9a87c2f62fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Cardiac Dysfunction
</title>
                     <text>
                        <paragraph>In INVICTUS, cardiac failure occurred in 1.2% of the 85 patients who received QINLOCK. In the pooled safety population, cardiac dysfunction (including cardiac failure, acute left ventricular failure, diastolic dysfunction, and ventricular hypertrophy) occurred in 1.7% of patients, including Grade 3 adverse reactions in 1.1%.</paragraph>
                        <paragraph>In INVICTUS, Grade 3 decreased ejection fraction occurred in 1.3% of the 77 patients who received QINLOCK and who had a baseline and at least one post-baseline echocardiogram. In the pooled safety population, Grade 3 decreased ejection fraction occurred in 1.9% of the 263 patients who received QINLOCK and who had a baseline and at least one post-baseline echocardiogram.</paragraph>
                        <paragraph>In INVICTUS, cardiac dysfunction led to dose discontinuation in 1.2% of the 85 patients who received QINLOCK. The safety of QINLOCK has not been assessed in patients with a baseline ejection fraction below 50%.</paragraph>
                        <paragraph>Assess ejection fraction by echocardiogram or MUGA scan prior to initiating QINLOCK and during treatment, as clinically indicated. Permanently discontinue QINLOCK for Grade 3 or 4 left ventricular systolic dysfunction <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s5">2.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="f35037c5-ce97-4c1c-a175-8f1ba871ced7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Risk of Impaired Wound Healing
</title>
                     <text>
                        <paragraph>Impaired wound healing complications can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, QINLOCK has the potential to adversely affect wound healing.</paragraph>
                        <paragraph>Withhold QINLOCK for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of QINLOCK after resolution of wound healing complications has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="053fd32b-46cc-4cf8-b478-2e92575ad978"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Photosensitivity
</title>
                     <text>
                        <paragraph>QINLOCK may cause photosensitivity reactions.  In all patients treated with QINLOCK in clinical trials (n=621), photosensitivity reactions occurred in 0.6% of patients.
</paragraph>
                        <paragraph>Advise patients to limit direct ultraviolet exposure during treatment with QINLOCK and for at least one week after discontinuation of treatment.
</paragraph>
                     </text>
                     <effectiveTime value="20231031"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="c492d9de-a41e-4069-a373-75cd605116b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Embryo-Fetal Toxicity
</title>
                     <text>
                        <paragraph>Based on findings from animal studies and its mechanism of action, QINLOCK can cause fetal harm when administered to a pregnant woman. Oral administration of ripretinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations primarily associated with the cardiovascular and skeletal systems, anatomic variations, decreased fetal body weight, and increased post-implantation loss at exposures approximately one half of the recommended dose of 150 mg once daily based on area under the curve (AUC).
</paragraph>
                        <paragraph>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with QINLOCK and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with QINLOCK and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s25">8.1</linkHtml>, <linkHtml href="#s31">8.3</linkHtml>), Nonclinical Toxicology (<linkHtml href="#s53">13.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="eb03026e-3c7a-41de-8da7-bd8b8e097575"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed elsewhere in the labeling:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Palmar-Plantar Erythrodysesthesia Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>
                     </item>
                     <item>New Primary Cutaneous Malignancies <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>
                     </item>
                     <item>Hypertension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)]</content>
                     </item>
                     <item>Cardiac Dysfunction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>
                     </item>
                     <item>Photosensitivity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.6</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20220927"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (â¥20%) were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia, and vomiting. The most common Grade 3 or 4  laboratory abnormalities (â¥4%) were increased lipase and decreased phosphate. (<linkHtml href="#s18">6.1</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Deciphera Pharmaceuticals, LLC, at 1-888-724-3274 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s18">
                     <id root="3699198d-b408-40ea-a149-3cfaf363bd2e"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                        <paragraph>Unless otherwise specified, the pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to QINLOCK as a single agent in 351 patients with advanced solid tumors enrolled in either an open-label dose finding with cohort expansion trial or INVICTUS. Among the patients who received QINLOCK in these trials, 52% were exposed for 6 months or longer and 21% were exposed for greater than one year.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                     <component>
                        <section ID="s19">
                           <id root="f152e622-b480-460e-b024-2d8003648301"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Gastrointestinal Stromal Tumor</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s20">
                           <id root="32be28c0-7efe-4538-8a7c-e5f70ed5273b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Patients Who Received Prior Treatment with Imatinib, Sunitinib and Regorafenib</content>
                              </paragraph>
                              <paragraph>The safety of QINLOCK was evaluated in INVICTUS <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s54">14</linkHtml>)]</content>. Patients received QINLOCK 150 mg taken orally once daily (n=85) or placebo (n=43). Among the patients who received QINLOCK, 46% were exposed for 6 months or longer and 3.5% were exposed for greater than one year.
</paragraph>
                              <paragraph>Serious adverse reactions occurred in 31% of patients who received QINLOCK. Serious adverse reactions that occurred in &gt;2% of patients were abdominal pain (4.7%), anemia (3.5%), nausea (2.4%), and vomiting (2.4%).
</paragraph>
                              <paragraph>Permanent discontinuation due to an adverse reaction occurred in 8% of patients who received QINLOCK. Adverse reactions resulting in permanent discontinuation in â¥1% of patients included general physical health deterioration (2.4%), anemia (1.2%), cardiac failure (1.2%), PPES (1.2%), and vomiting (1.2%).
</paragraph>
                              <paragraph>Dosage interruptions due to an adverse reaction occurred in 24% of patients who received QINLOCK. Adverse reactions requiring dosage interruption in &gt;2% of patients included nausea (3.5%), increased blood bilirubin (2.4%), and PPES (2.4%).
</paragraph>
                              <paragraph>Dose reductions due to an adverse reaction occurred in 7% of patients who received QINLOCK. Adverse reactions resulting in a dose reduction in â¥1.2% of patients were abdominal pain, agitation, alopecia, arthritis, dermatosis, gastrointestinal disorder, hyperesthesia, myalgia, PPES, and decreased weight.
</paragraph>
                              <paragraph>The most common adverse reactions (â¥20%), were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, PPES, and vomiting. The most common Grade 3 or 4 laboratory abnormalities (â¥4%) were increased lipase and decreased phosphate.
</paragraph>
                              <paragraph>
                                 <linkHtml href="#t2">Table 2</linkHtml> summarizes the adverse reactions in INVICTUS.
</paragraph>
                              <table ID="t2" width="100%">
                                 <caption>Table 2: Adverse Reactions (â¥10%) in Patients with Gastrointestinal Stromal Tumor Who Received QINLOCK in INVICTUS
</caption>
                                 <col width="39.140%" align="left"/>
                                 <col width="15.220%" align="left"/>
                                 <col width="15.220%" align="left"/>
                                 <col width="15.220%" align="left"/>
                                 <col width="15.200%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reaction</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">QINLOCK<br/>(N=85)</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Placebo <br/>(N=43)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grades 1-4</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grades 3-4</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grades 1-4</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grades 3-4</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Skin and subcutaneous tissue</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Alopecia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">52
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Palmar-plantar erythrodysesthesia syndrome
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dry skin
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pruritus
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">General</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fatigue
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">42
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.3
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Peripheral edema
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">17
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Asthenia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.7
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">39
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Abdominal pain
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">36
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">30
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.7
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Constipation
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">34
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">28
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.3
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Vomiting
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Stomatitis
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Musculoskeletal and connective tissue</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Myalgia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">32
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Arthralgia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">18
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Muscle spasms
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">15
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Metabolism and nutrition</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased appetite
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">27
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.3
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Investigations</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased weight
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Nervous system</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Vascular</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypertension
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">14
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">7
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">4.7
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Respiratory, thoracic and mediastinal</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dyspnea
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <linkHtml href="#t3">Table 3</linkHtml> summarizes the laboratory abnormalities in INVICTUS.
</paragraph>
                              <table ID="t3" width="100%">
                                 <caption>Table 3: Select Laboratory Abnormalities (â¥10%) Worsening from Baseline in Patients with Gastrointestinal Stromal Tumor Who Received QINLOCK with a Difference Between Arms of &gt;5% Compared to Placebo in INVICTUS
</caption>
                                 <col width="43.380%" align="left"/>
                                 <col width="14.160%" align="left"/>
                                 <col width="14.160%" align="left"/>
                                 <col width="14.160%" align="left"/>
                                 <col width="14.140%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Lrule Rrule">
                                          <paragraph styleCode="footnote">CPK=creatine phosphokinase; INR=international normalized ratio; AST=aspartate aminotransferase; ALT=alanine aminotransferase
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Lrule Rrule">
                                          <paragraph styleCode="footnote">
                                             <sup>a.</sup> The denominator used to calculate the rate varied from 82 to 83 for QINLOCK and 34 to 40 for placebo based on the number of patients with a baseline value and at least one post-treatment value.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <paragraph styleCode="footnote">
                                             <sup>b.</sup> Only includes Grade 3 laboratory abnormalities.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Laboratory Abnormality</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">QINLOCK</content>
                                          <content styleCode="bold">
                                             <sup>a</sup>
                                          </content>
                                          <content styleCode="bold">
                                             <br/>(N=85)</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Placebo</content>
                                          <content styleCode="bold">
                                             <sup>a
</sup>
                                          </content>
                                          <content styleCode="bold">
                                             <br/>(N=43)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grades 1-4</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grades 3-4</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grades 1-4</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Grades 3-4</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Hematology</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased activated partial thromboplastin time
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">35
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased INR
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">15
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased neutrophil count
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="bold">Chemistry</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased lipase
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">32
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased phosphate
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">26
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased triglycerides
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">26
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.4
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased calcium
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased blood bilirubin
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">22
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.5
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased CPK
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased sodium
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">17
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.4
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.5
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased creatinine
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">16
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">18
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased serum amylase
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Increased ALT
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s21">
                           <id root="d779939d-16a9-402f-b0e0-d8a500d30013"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Adverse Reactions</content>
                              </paragraph>
                              <paragraph>Clinically relevant adverse reactions that occurred in &lt;10% of QINLOCK-treated patients in INVICTUS included peripheral sensory neuropathy, dermatitis acneiform, and rash.
                    </paragraph>
                              <paragraph>Clinically relevant adverse reactions that occurred in &lt;10% of patients in the pooled safety population included cardiac ischemic events (including acute coronary syndrome and fatal cardiac arrest or myocardial infarction). Photosensitivity occurred in 0.6% <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.6</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20231031"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s22">
               <id root="239f15c1-c6b8-44c3-bafb-758e3fed6ffe"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <effectiveTime value="20220927"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Strong CYP3A Inhibitors</content>: Monitor more frequently for adverse reactions. (<linkHtml href="#s23">7.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Strong CYP3A Inducers</content>: Avoid concomitant use of strong CYP3A inducers. (<linkHtml href="#s23">7.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Moderate CYP3A Inducers</content>: Avoid concomitant use of moderate CYP3A inducers. If a moderate CYP inducer cannot be avoided, increase ripretinib dose frequency to twice daily. (<linkHtml href="#s6">2.3</linkHtml>, <linkHtml href="#s23">7.1</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s23">
                     <id root="b0763a46-5191-4972-9792-689924722e37"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on QINLOCK
</title>
                     <text>
                        <paragraph>
                           <linkHtml href="#t4">Table 4</linkHtml> includes drug interactions that affect the pharmacokinetics of ripretinib.
</paragraph>
                        <table ID="t4" width="100%">
                           <caption>Table 4: Drug Interactions that Affect QINLOCK
</caption>
                           <col width="25.650%" align="left"/>
                           <col width="74.350%" align="left"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="underline">Strong CYP3A Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Coadministration of QINLOCK with a strong CYP3A inhibitor increased the exposure of ripretinib and its active metabolite (DP-5439), which may increase the risk of adverse reactions <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s47">12.3</linkHtml>)].</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Monitor patients more frequently for adverse reactions.
</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="underline">Strong and Moderate CYP3A Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Coadministration of QINLOCK with a strong CYP3A inducer decreased the exposure of ripretinib and its active metabolite (DP-5439), which may decrease QINLOCK anti-tumor activity <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s47">12.3</linkHtml>)]</content>.
</item>
                                       <item>Coadministration of QINLOCK with moderate CYP3A inducers is predicted to decrease the exposure of ripretinib and its active metabolite (DP-5439), which may decrease QINLOCK anti-tumor activity <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s47">12.3</linkHtml>)]</content>.
</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Avoid concomitant use of QINLOCK with strong CYP3A inducers.</item>
                                       <item>Avoid concomitant use of QINLOCK with moderate CYP3A inducers. If a moderate CYP3A inducer cannot be avoided, increase QINLOCK dosing frequency from the recommended dose of 150 mg once daily to 150 mg twice daily during the co-administration period. Monitor for clinical response and tolerability <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s6">2.3</linkHtml>)]</content>.
</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s24">
               <id root="11c57f29-f015-499c-a09f-a37dd16ac9d2"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20221229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#s29">8.2</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s25">
                     <id root="a34afa9b-0842-49ba-a7a1-43d32aa67a6b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20220927"/>
                     <component>
                        <section ID="s26">
                           <id root="ad5914e8-7b31-43d9-962f-1a0df4791572"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on findings from animal studies and its mechanism of action <content styleCode="italics">[seeÂ Clinical Pharmacology (<linkHtml href="#s43">12.1</linkHtml>)]</content>, QINLOCK can cause fetal harm when administered to a pregnant woman. There are no available data on the use of QINLOCK in pregnant women to inform a drug-associated risk. Administration of ripretinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations primarily associated with the cardiovascular and skeletal systems, anatomic variations, reduced fetal body weight, and increased post-implantation loss at maternal exposures that were approximately equal to the human exposure at the recommended dose of 150 mg (seeÂ <content styleCode="italics">
                                    <linkHtml href="#s27">Data</linkHtml>
                                 </content>). Advise pregnant women of the potential risk to a fetus.
</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s27">
                           <id root="89799d49-f0f5-47a3-8c31-898797b1142b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                           <component>
                              <section ID="s28">
                                 <id root="364d02ca-7c35-4223-a67f-fc33f362fcef"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal development study investigating daily doses of ripretinib administered during the period of organogenesis in rats,Â ripretinib resulted in malformations primarily associated with the cardiovascular and skeletal systems, including interrupted or retroesophageal aortic arch and retroesophageal subclavian artery, fusion of the exoccipital bone to the first cervical vertebra, branched and fused ribs, anomalies of the cervical, thoracic, caudal, and sacral vertebrae, absent forepaw phalanges, and absent metacarpals at a dose of 20Â mg/kg/day (approximately one half of the human exposure at the recommended dose of 150 mg). An increased incidence of anatomic variations were also observed at 20Â mg/kg/day. Variations included malpositioned carotid and subclavian artery origins, malpositioned subclavian artery, absent or elongated innominate artery, misshapen and nodulated ribs, bipartite, incompletely ossified, or unossified vertebral centra, small or misshapen vertebral arches, and reductions in ossified forelimb and hindlimb phalanges, hindlimb metatarsals, and caudal vertebrae.
</paragraph>
                                    <paragraph>In a preliminary embryo-fetal development study investigating the administration of ripretinib in rabbits during the period of organogenesis, ripretinib resulted in total loss of pregnancy at doses of 150 mg/kg (approximately 3.5 times the human exposure at the recommended dose of 150 mg). At a dose of 40 mg/kg (approximately 2.1Â times the human exposure at the recommended dose of 150 mg), toxicities included increased post-implantation loss and decreased fetal body weights.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220927"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s29">
                     <id root="93e7f051-eb2a-447e-aba0-91e5190b0009"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20220927"/>
                     <component>
                        <section ID="s30">
                           <id root="d58ddcbf-6859-44a2-9e2a-c0a468317ae9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data regarding the presence of ripretinib or its metabolites in either human milk or its effects on a breastfed child or on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with QINLOCK and for 1 week after the last dose.
</paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="e64c4f4b-9651-4124-a3a1-67b1ac0ac692"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential
</title>
                     <text>
                        <paragraph>QINLOCK can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[seeÂ Use in Specific Populations (<linkHtml href="#s25">8.1</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                     <component>
                        <section ID="s32">
                           <id root="a3a0f080-2d55-4a08-8abc-53f72f2f7556"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify pregnancy status of females of reproductive potential prior to the initiation of QINLOCKÂ <content styleCode="italics">[seeÂ Use in Specific Populations (<linkHtml href="#s25">8.1</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s33">
                           <id root="43915cba-aaf0-4e13-a629-c2a728b0d3b6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                           <component>
                              <section ID="s34">
                                 <id root="97c6f2bc-3a37-44f3-8c66-4cb4ff8fbc3e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220927"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s35">
                                 <id root="0380efee-fa54-43dc-b95d-c71e60be4ddb"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.
</paragraph>
                                 </text>
                                 <effectiveTime value="20220927"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s36">
                           <id root="95ac7e7b-8dab-4d28-8fd0-9c9ff186e1e5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                              <paragraph>Based on findings from animal studies, QINLOCK may impair fertility in males of reproductive potential <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#s53">13.1</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s37">
                     <id root="13a147c6-fa15-459a-b997-eb9833e98be7"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of QINLOCK in pediatric patients have not been established.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                     <component>
                        <section ID="s38">
                           <id root="7cc20bde-3749-4b83-bd10-d28802593bde"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Animal Toxicity Data</content>
                              </paragraph>
                              <paragraph>In 13-week repeat-dose studies in rats there were dose-dependent findings of increased osteoblastic surface and decreased trabeculae of the femur at doses â¥30 mg/kg/day (approximately one half of the human exposure at the recommended dose of 150 mg). There were additional findings of missing or discolored teeth that were accompanied by dose-dependent incisor degeneration at doses â¥30 mg/kg/day.
</paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s39">
                     <id root="792f9603-267f-4c49-beeb-3fef9d7ca6c9"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>Of the 85 patients in INVICTUS who received QINLOCK 150 mg orally once daily, 24% were between 65 to 74 years of age and 9% were 75 years of age or older. Clinical studies of QINLOCK did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s40">
                     <id root="cc71eb5d-7888-437b-b1a0-c9c94a4dfb05"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment
</title>
                     <text>
                        <paragraph>No dose adjustment is recommended in patients with hepatic impairment (Child-Pugh A, B, or C) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s47">12.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20231031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s41">
               <id root="9431ab88-f2ad-4e90-8069-43ab9215658b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>Ripretinib is a kinase inhibitor. The chemical name of ripretinib is 1-(4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl)-3-phenylurea. The molecular formula is C<sub>24</sub>H<sub>21</sub>BrFN<sub>5</sub>O<sub>2</sub> and the molecular weight is 510.36 g/mol. The chemical structure of ripretinib is shown below:
</paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Ripretinib is a white to off-white crystalline solid. Ripretinib is a lipophilic, weak base, and practically insoluble in aqueous media.
</paragraph>
                  <paragraph>QINLOCK is available as a white to off-white, oval tablets for oral use containing 50 mg of ripretinib. The tablet is debossed with âDC1â on one side. Each tablet contains the following inactive ingredients: crospovidone, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and silicon dioxide.
</paragraph>
               </text>
               <effectiveTime value="20231031"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qin00-0005-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s42">
               <id root="c639f90a-112f-4d8d-bbf8-074dd36fe586"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20250512"/>
               <component>
                  <section ID="s43">
                     <id root="7b36d198-6489-4de2-9ff7-a5d2aed1cb74"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases inÂ vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="s44">
                     <id root="ed35421d-9056-4450-a5de-6b98abb76065"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <effectiveTime value="20220927"/>
                     <component>
                        <section ID="s45">
                           <id root="0093bb93-3571-408d-81fd-69098423b7ae"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Exposure-Response Relationships</content>
                              </paragraph>
                              <paragraph>Ripretinib exposure-response relationships and the time course of pharmacodynamics have not been fully characterized.
</paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s46">
                           <id root="4f043eaf-4b13-4935-bf5b-57d657c0f5ba"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>No large mean increase in QTc interval (i.e. &gt;20 ms) was detected following treatment with QINLOCK at the recommended dose of 150Â mg taken orally once daily.
</paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s47">
                     <id root="4545d363-d84e-4ed5-9d7a-5ccfa2c4c418"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <text>
                        <paragraph>The pharmacokinetics of ripretinib and its equally active metabolite (DP-5439) were characterized in clinical studies. In patients with advanced malignancies, ripretinib AUC<sub>0-24h</sub> increased proportionally over a dose range of 20-250 mg (0.13 to 1.67 times the recommended dose), but C<sub>max</sub> was less than dose proportional; DP-5439 C<sub>max</sub> and AUC<sub>0-24h</sub> were less than dose proportional within the dose range of 50-250 mg (0.33 to 1.67 times the recommended dose).
</paragraph>
                        <paragraph>No clinically significant differences in the C<sub>max</sub> and AUC<sub>0-24h</sub> were observed between administration of QINLOCK with a high-fat meal (150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively) and under fasted conditions. The pharmacokinetic parameters of ripretinib and DP-5439 are summarized in <linkHtml href="#t5">Table 5</linkHtml>.
</paragraph>
                        <table ID="t5" width="100%">
                           <caption>Table 5: Pharmacokinetic Parameters of Ripretinib and DP-5439
</caption>
                           <col width="15.729%" align="left"/>
                           <col width="13.278%" align="left"/>
                           <col width="34.334%" align="left"/>
                           <col width="36.659%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                                    <paragraph styleCode="footnote">
                                       <sup>a.</sup> Estimated based on cycle 1, day 15
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                                    <paragraph styleCode="footnote">
                                       <sup>b.</sup> After a single oral dose of 150 mg
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <paragraph styleCode="footnote">CV=coefficient of variation; C<sub>max</sub>=maximum plasma concentration; AUC<sub>0-12h</sub>=area under the plasma concentration-time curve from time zero to 12 hours; AUC<sub>0-24h</sub>=area under the plasma concentration-time curve from time zero to 24 hours; T<sub>max</sub>=time to maximum concentration
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Parameter</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Ripretinib</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">DP-5439</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="underline">General Information</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Steady state exposure following QINLOCK 150Â mg once daily<br/>[Mean (CV%)]
</td>
                                 <td align="left" valign="middle" styleCode="Botrule Rrule">C<sub>max</sub> (ng/mL)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">761 (32)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">804 (46)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Rrule">AUC<sub>0-12h</sub> (ngâ¢h/mL)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">5678 (32)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">7138 (44)
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Time to steady state [Days]
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">14
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">14
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Accumulation ratio (AUC<sub>0-12h</sub>)<br/>[Mean (CV%)]<sup>a</sup>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">1.7 (55)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">5.29 (49)
</td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="underline">Absorption</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">T<sub>max</sub> [Median in hours]<sup>b</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">15.6
</td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="underline">Distribution</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Plasma protein binding (in vitro)
</td>
                                 <td align="left" valign="middle" styleCode="Botrule Rrule">Human serum albumin
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">99.8%
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">99.7%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Rrule">Î±-1 acid glycoprotein
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">99.4%
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">&gt;99.8%
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Steady state apparent volume of distribution, L <br/>[Mean (CV%)]<sup>b</sup>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">307 (39)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">507 (51)
</td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="underline">Elimination</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Apparent clearance, L/hr <br/>[Mean (CV%)]<sup>b</sup>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">15.3 (45)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">17.5 (63)
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Half-life, hours  <br/>[Mean (CV%)]<sup>b</sup>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">14.8 (30)
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">17.8 (23)
</td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Metabolism</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Metabolic pathways
</td>
                                 <td align="left" valign="middle" styleCode="Botrule Rrule">Major
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">CYP3A4
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">CYP3A4
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Rrule">Minor
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">CYP2C8 and CYP2D6
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">CYP2C8, CYP2E1 and CYP2D6
</td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Excretion</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">Excretion pathways
</td>
                                 <td align="left" valign="middle" styleCode="Botrule Rrule">Feces
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">34%
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">6%
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Rrule">Urine
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">0.02%
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">0.1%
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250512"/>
                     <component>
                        <section ID="s48">
                           <id root="69de7513-0924-4b3a-bf0c-fc0fe59a9ba6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of ripretinib were observed based on age (19 to 87Â years), sex, race (White, Black, and Asian), body weight (39 to 138 kg), tumor (GIST or other solid tumors), prior gastrectomy, mild to moderate renal impairment (CLcr 30 to &lt;90 mL/min estimated by Cockcroft-Gault), and mild hepatic impairment (total bilirubin â¤ULN and AST &gt;ULN or total bilirubin 1 to 1.5Â Ã ULN and AST any).</paragraph>
                              <paragraph>The effects of severe renal impairment (CLcr 15 to 29 mL/min) on the pharmacokinetics of ripretinib have not been studied.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Patients with Hepatic Impairment</content>
                              </paragraph>
                              <paragraph>In subjects with mild hepatic impairment, there were no clinically significant changes in AUC<sub>0-last</sub> and C<sub>max</sub> when compared to matched healthy subjects.</paragraph>
                              <paragraph>In subjects with moderate hepatic impairment, ripretinib AUC<sub>0-last</sub> increased 2-fold while C<sub>max</sub> was unchanged when compared to matched healthy subjects. The combined AUC<sub>0-last</sub> of ripretinib and DP-5439 increased 1.5-fold.</paragraph>
                              <paragraph>In subjects with severe hepatic impairment, ripretinib AUC<sub>0-last</sub> increased 2.6-fold and C<sub>max</sub> decreased by 24% when compared to matched healthy subjects. The combined AUC<sub>0-last</sub> of ripretinib and DP-5439 increased by 1.4-fold.</paragraph>
                              <paragraph>The observed magnitude of increase in ripretinib and the combination of ripretinib and DP-5439 exposures in subjects with hepatic impairment is unlikely to be clinically relevant based on the known safety profile of ripretinib.</paragraph>
                           </text>
                           <effectiveTime value="20250512"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s49">
                           <id root="e65df7af-bc74-433b-bfa6-868fcac8a617"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250512"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s50">
                           <id root="af52eb66-7c8f-4733-8c30-c824943dcbca"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Clinical Studies and Model-Informed Approaches</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">CYP Enzymes:</content> No clinically significant differences in the pharmacokinetics of repaglinide (a sensitive substrateÂ for CYP2C8) were observed when used concomitantly with QINLOCK.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Strong CYP3A Inhibitors:</content> Coadministration of QINLOCK with itraconazole (a strong CYP3A inhibitor and also a P-gp inhibitor) increased ripretinib C<sub>max</sub> by 36% and AUC<sub>0-inf</sub> by 99% and also increased DP-5439 AUC<sub>0-inf</sub> by 99% with no change in its C<sub>max</sub>.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">ï»¿Strong CYP3A Inducers:</content> Coadministration of QINLOCK with rifampin (a strong CYP3A inducer) decreased ripretinib C<sub>max</sub> by 18% and AUC<sub>0-inf</sub> by 61% and also decreased DP-5439 AUC<sub>0-inf</sub> by 57% with increased C<sub>max</sub> by 37%.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Moderate CYP3A Inducers:</content> Coadministration of QINLOCK with efavirenz (a moderate CYP3A inducer) was predicted to decrease ripretinib C<sub>max</sub> by 24% and decrease AUC<sub>0-inf</sub> by 56%.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Proton Pump Inhibitors:</content> No clinically significant differences in the plasma exposure to ripretinib and DP-5439 were observed when QINLOCK was coadministered with pantoprazole (a proton pump inhibitor).</paragraph>
                           </text>
                           <effectiveTime value="20250512"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s51">
                           <id root="7b7b2240-452f-4c4a-b216-039605b0b12b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">In Vitro Studies</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">CYP Enzymes:</content>Â Ripretinib and DP-5439 are not inducers of CYP1A2, CYP2B6, or CYP3A4.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Transporter Systems:</content> Ripretinib and DP-5439 are substrates for P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Ripretinib is an inhibitor of P-gp and BCRP. DP-5439 is an inhibitor of BCRP and Multidrug And Toxin Extrusion Protein 1 (MATE1).</paragraph>
                              <paragraph>
                                 <content styleCode="italics">UGT1A Substrates:</content> Ripretinib is an inhibitor of UGT1A1, UGT1A3, UGT1A4, UGT1A7, and UGT1A8.</paragraph>
                           </text>
                           <effectiveTime value="20250512"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s52">
               <id root="bf3c7f8d-6e9b-4532-91e6-fe3612f21668"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20220927"/>
               <component>
                  <section ID="s53">
                     <id root="3c536f5f-50de-48fd-b05a-8b680eefe2a0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with ripretinib.
</paragraph>
                        <paragraph>Ripretinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in either an in vitro human lymphocyte culture micronucleus assay or an in vivo rat bone marrow micronucleus assay.
</paragraph>
                        <paragraph>Dedicated fertility studies in male animals were not conducted with ripretinib. Findings in male reproductive organs occurred in repeat-dose toxicity studies and included degeneration of the testes and cellular debris of the epididymis in males administered â¥30 mg/kg/day (approximately one half of the human exposure at the recommended dose of 150 mg).
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s54">
               <id root="1df43387-ef2e-4ad7-9b06-b8361cddd493"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <text>
                  <paragraph>The efficacy of QINLOCK was evaluated in INVICTUS, an international, multi-center, randomized (2:1), double-blind, placebo-controlled trial (NCT03353753). Eligible patients had unresectable, locally advanced or metastatic gastrointestinal stromal tumor (GIST) and had received prior treatment with imatinib, sunitinib, and regorafenib. Randomization was stratified by prior lines of therapy (3 versus â¥4) and Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1 or 2). Patients received QINLOCK 150 mg or placebo orally once daily until disease progression or unacceptable toxicity. Tumor response assessments were performed every 28 days through for the first 4 months and then every 56 days thereafter. The major efficacy outcome measure was progression-free survival (PFS) based on disease assessment by blinded independent central review (BICR) using modified RECIST 1.1 criteria, in which lymph nodes and bone lesions were not target lesions and a progressively growing new tumor nodule within a pre-existing tumor mass must meet specific criteria to be considered unequivocal evidence of progression. Additional efficacy outcome measures included objective response rate (ORR) by BICR and overall survival (OS). Patients randomized to receive placebo could be treated with QINLOCK at the time of disease progression.
</paragraph>
                  <paragraph>A total of 129 patients were randomized, 85 to QINLOCK and 44 to placebo.
</paragraph>
                  <paragraph>Patient characteristics of the intent-to-treat (ITT) population in INVICTUS were median age of 60 years (range: 29 to 83 years), with 39% aged â¥65 years; 57% were male; 75% were White; and 92% had an ECOG performance status of 0 or 1. Sixty-three percent (63%) of patients received 3 prior therapies and 37% received 4 or more prior therapies. Sixty-six percent (66%) of patients randomized to placebo switched to QINLOCK after disease progression.
</paragraph>
                  <paragraph>Efficacy results from INVICTUS are summarized in <linkHtml href="#t6">Table 6</linkHtml>.
</paragraph>
                  <table ID="t6" width="100%">
                     <caption>Table 6: Efficacy Results of INVICTUS
</caption>
                     <col width="44.967%" align="left"/>
                     <col width="28.300%" align="left"/>
                     <col width="26.733%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <paragraph styleCode="footnote">BICR=Blinded Independent Central Review; CI=Confidence Interval
</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <paragraph styleCode="footnote">
                                 <sup>a.</sup> Assessed per BICR.
</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <paragraph styleCode="footnote">
                                 <sup>b.</sup> p-value is based on 2-sided stratified log-rank test.
</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <paragraph styleCode="footnote">
                                 <sup>c.</sup> Hazard ratio is based on Cox proportional regression model. This model includes treatment and randomization stratification factors as fixed factors.
</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <paragraph styleCode="footnote">
                                 <sup>d.</sup> Based on Fisher's exact test. The p-value is not statistically significant.
</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <paragraph styleCode="footnote">
                                 <sup>e.</sup> Not evaluated for statistical significance as a result of the sequential testing procedure for the secondary endpoints of ORR and OS.
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">QINLOCK<br/>(N=85)</content>
                           </td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Placebo<br/>(N=44)</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Progression-Free Survival</content>
                              <content styleCode="bold">
                                 <sup>a</sup>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Number of events (%)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">51 (60)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">37 (84)
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Progressive disease
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">46 (54)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">32 (73)
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Deaths
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">5 (6)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">5 (11)
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Median PFS (months) (95% CI)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">6.3 (4.6, 6.9)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">1.0 (0.9, 1.7)
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hazard ratio (95% CI)<sup>c</sup>
                           </td>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">0.15 (0.09, 0.25)
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">p-value<sup>b</sup>
                           </td>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">&lt; 0.0001
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Overall Response Rate</content>
                              <content styleCode="bold">
                                 <sup>a</sup>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Overall Response Rate (%)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">(95% CI)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">(4.2, 18)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">(0, 8)
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">p-value<sup>d</sup>
                           </td>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">0.0504
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Overall Survival
</content>
                              <sup>e</sup>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Number of deaths (%)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">26 (31)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">26 (59)
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Median OS (months) (95% CI)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">15.1 (12.3, 15.1)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">6.6 (4.1, 11.6)
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hazard ratio (95% CI)<sup>c</sup>
                           </td>
                           <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">0.36 (0.21, 0.62)
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Kaplan-Meier Curve of Progression-Free Survival in INVICTUS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f02" referencedObject="mm02"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2: Kaplan-Meier Curve of Overall Survival in INVICTUS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f03" referencedObject="mm03"/>
                  </paragraph>
               </text>
               <effectiveTime value="20231031"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Figure 1
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qin00-0005-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm03">
                     <text>Figure 2
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qin00-0005-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s55">
               <id root="61f58645-8b75-471d-a5d9-15fa2fc8b246"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>QINLOCK 50 mg tablets are white to off-white, oval shaped, and debossed with âDC1â on one side.
</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption/>90-count bottlesÂ  Â  Â  Â  Â  Â  NDC 73207-101-30
</item>
                  </list>
                  <paragraph>Dispense in original container only. Store in the original container with the desiccant to protect from moisture and light. Replace cap securely each time after opening. Do not discard desiccant.
</paragraph>
                  <paragraph>Store at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursion permitted between 15Â°C to 30Â°C (59Â°F to 86Â°F) <content styleCode="italics">[see USP Controlled Room Temperature]</content>.
</paragraph>
               </text>
               <effectiveTime value="20231031"/>
            </section>
         </component>
         <component>
            <section ID="s56">
               <id root="57201987-4759-4e35-89a1-92198164b5cb"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#s68">Patient Information</linkHtml>).
</paragraph>
               </text>
               <effectiveTime value="20231031"/>
               <component>
                  <section ID="s57">
                     <id root="aa87de2f-b78f-455e-bd60-b696dd75c3f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Palmar-Plantar Erythrodysesthesia Syndrome</content>
                        </paragraph>
                        <paragraph>Advise patients to contact their healthcare provider immediately if they experience severe skin changes <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s58">
                     <id root="50cd2745-30b9-4655-b0a4-9e6e01c3873f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">New Primary Cutaneous Malignancies</content>
                        </paragraph>
                        <paragraph>Advise patients to contact their healthcare provider immediately for change in or development of new skin lesions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s59">
                     <id root="560ad5b2-302b-4b12-8cb0-183fcf52f520"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypertension</content>
                        </paragraph>
                        <paragraph>Advise patients that hypertension may develop during treatment with QINLOCK and that blood pressure should be monitored regularly during treatment <content styleCode="italics">[</content>
                           <content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s60">
                     <id root="af4d4b99-d47f-441d-a74c-a9590806821a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Dysfunction</content>
                        </paragraph>
                        <paragraph>Advise patients that cardiac failure may develop during treatment with QINLOCK and that signs or symptoms of cardiac failure should be regularly monitored during treatment. Advise patients to contact their healthcare provider immediately for signs or symptoms of cardiac dysfunction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s61">
                     <id root="2b291a09-828e-46bd-aa30-814d4588cda3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk of Impaired Wound Healing</content>
                        </paragraph>
                        <paragraph>Advise patients that QINLOCK may impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedure <content styleCode="italics">[see Warnings and PrecautionsÂ (<linkHtml href="#s14">5.5</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s62">
                     <id root="b0470cea-6479-4452-8b0a-48130addf2cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Photosensitivity</content>
                        </paragraph>
                        <paragraph>Inform patients that there is a potential risk of photosensitivity reactions with QINLOCK. Advise patients to limit direct ultraviolet exposure by using sunscreen and protective clothing during treatment with QINLOCK <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.6</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.7</linkHtml>), Use in Specific Populations (<linkHtml href="#s25">8.1</linkHtml>)]</content>.
</item>
                           <item>Advise females of reproductive potential to use effective contraception during treatment with QINLOCK and for 1 week after the last doseÂ <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s31">8.3</linkHtml>)].</content>
                           </item>
                           <item>Advise males with female partners of reproductive potential to use effective contraception during treatment with QINLOCK and for 1 week after the last doseÂ <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s31">8.3</linkHtml>), Nonclinical Toxicology (<linkHtml href="#s53">13.1</linkHtml>)]</content>.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20231031"/>
                  </section>
               </component>
               <component>
                  <section ID="s63">
                     <id root="1c616042-77a6-4bf2-8550-2ab4f1a9d768"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise females not to breastfeed during treatment with QINLOCK and for 1 week after the last doseÂ <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s29">8.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s64">
                     <id root="8d4c5716-e1f0-4857-84f4-31d01b5a5ad7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Advise males of reproductive potential that QINLOCK may impair fertility <content styleCode="italics">[see Use in Specific Populations </content>
                           <content styleCode="italics">(<linkHtml href="#s31">8.3</linkHtml>),
</content>
                           <content styleCode="italics">Nonclinical Toxicology (<linkHtml href="#s53">13.1</linkHtml>)</content>
                           <content styleCode="italics">]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
               <component>
                  <section ID="s65">
                     <id root="6e48e9fa-ee1c-4bdf-94c5-765fad95a41a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s23">7.1</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                     <component>
                        <section ID="s66">
                           <id root="8591656f-1d0c-4a83-bcb2-843e0b6b1917"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage and Administration</content>
                              </paragraph>
                              <paragraph>Instruct patients to take QINLOCK at the same time each day (once daily) with or without food. Advise patients to swallow tablets whole. Inform patients about what to do in the event they miss a dose or vomit after taking a dose of QINLOCK <content styleCode="italics">[see Dosage and Administration
</content>
                                 <content styleCode="italics">(<linkHtml href="#s4">2.1</linkHtml>)</content>
                                 <content styleCode="italics">]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20220927"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s67">
                     <id root="8c95d808-299b-4828-ae5c-41f449491a4e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage Instructions</content>
                        </paragraph>
                        <paragraph>Store QINLOCK in the original container at room temperature between 20ÂºC to 25ÂºC (68ÂºF to 77ÂºF).
</paragraph>
                        <paragraph>Manufactured for and marketed by:<br/>
                           <content styleCode="bold">Deciphera Pharmaceuticals, LLC <br/>
                           </content>200 Smith Street, Waltham, MA 02451
</paragraph>
                     </text>
                     <effectiveTime value="20220927"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s68">
               <id root="bdf6debb-3b48-413f-b22a-92ccd39552a4"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="50.000%" align="left"/>
                     <col width="25.000%" align="left"/>
                     <col width="25.000%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <paragraph styleCode="footnote">This Patient Information has been approved by the U.S. Food and Drug Administration.
</paragraph>
                           </td>
                           <td align="left" valign="top">
                              <paragraph styleCode="footnote">Revised: 10/2023
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Patient Information</content>
                              <br/>
                              <content styleCode="bold">QINLOCK</content>
                              <content styleCode="bold">
                                 <sup>Â®
</sup>
                              </content>
                              <content styleCode="bold">(kin-lok)</content>
                              <br/>
                              <content styleCode="bold">(ripretinib)</content>
                              <br/>
                              <content styleCode="bold">tablets</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What is QINLOCK?</content>
                              <br/>QINLOCK is a prescription medicine used to treat adults with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitor medicines, including imatinib, for their GIST.<br/>It is not known if QINLOCK is safe and effective in children.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before taking QINLOCK, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>had a type of skin problem called palmar-plantar erythrodysesthesia syndrome
</item>
                                 <item>have high blood pressure
</item>
                                 <item>have heart problems
</item>
                                 <item>had or plan to have surgery
</item>
                                 <item>are pregnant or plan to become pregnant. QINLOCK can harm your unborn baby. Tell your healthcare provider if you or your partner becomes pregnant or you think you may be pregnant during treatment with QINLOCK.<br/>
                                    <content styleCode="bold">Females who are able to become pregnant:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider will do a pregnancy test before you start treatment with QINLOCK.
</item>
                                       <item>You should use effective birth control (contraception) during treatment with QINLOCK and for 1Â week after the last dose. Talk to your healthcare provider about birth control methods that may be right for you.
</item>
                                    </list>
                                    <paragraph>
                                       <content styleCode="bold">Males with female partners who are able to become pregnant:</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>You should use effective birth control during treatment with QINLOCK and for at least 1 week after your final dose.
</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if QINLOCK passes into your breast milk. Do not breastfeed during treatment with QINLOCK and for at least 1 week after your final dose.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.<br/>QINLOCK and certain other medicines can affect each other causing side effects or affect how QINLOCK works.<br/>Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What should I avoid while taking QINLOCK?</content>
                              <br/>Your skin may be sensitive to the sun or other forms of light (photosensitivity) during treatment with QINLOCK. Avoid or limit exposure to direct sunlight, sunlamps, and other sources of ultraviolet radiation during treatment and for at least 1 week after stopping treatment with QINLOCK. Use sunscreen and wear clothes that cover your skin if you need to be out in the sun.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">How should I take QINLOCK?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take QINLOCK exactly as your healthcare provider tells you to.
</item>
                                 <item>Your healthcare provider may temporarily or permanently stop treatment or change your dose of QINLOCK if you develop side effects during treatment.
</item>
                                 <item>Do not change your dose or stop taking QINLOCK unless your healthcare provider tells you to.
</item>
                                 <item>Take QINLOCK 1 time each day, at the same time each day.
</item>
                                 <item>Take QINLOCK with or without food.
</item>
                                 <item>Swallow QINLOCK tablets whole.
</item>
                                 <item>If you vomit after taking a dose of QINLOCK, do not take an extra dose. Take your next dose of QINLOCK at your scheduled time.
</item>
                                 <item>If you miss a dose of QINLOCK, take it as soon as you remember if it is within 8 hours of the scheduled dose. If more than 8 hours have passed, wait until your next scheduled dose.
</item>
                                 <item>If you take more than the prescribed dose of QINLOCK, call your healthcare provider.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of QINLOCK?</content>
                              <br/>
                              <content styleCode="bold">QINLOCK may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">A skin problem called palmar-plantar erythrodysesthesia syndrome.</content> Skin problems are common and sometimes can be severe. Tell your healthcare provider right away if you develop redness, pain, blisters, bleeding, or swelling on the palms of your hands or soles of your feet, or severe rash during treatment with QINLOCK.
</item>
                                 <item>
                                    <content styleCode="bold">New skin cancers.</content> QINLOCK may cause skin cancers called cutaneous squamous cell carcinoma, keratoacanthoma, or melanoma.<br/>Talk to your healthcare provider about your risk for these cancers. Your healthcare provider should check your skin before and during treatment with QINLOCK to look for any new skin cancers.<br/>Check your skin and tell your healthcare provider right away about any skin changes, including a:<br/>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>new wart
</item>
                                       <item>skin sore or reddish bump that bleeds or does not heal
</item>
                                       <item>change in size or color of a mole
</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">High blood pressure (Hypertension).</content> High blood pressure is common with QINLOCK and can be severe. Your healthcare provider should check your blood pressure regularly during treatment with QINLOCK.
</item>
                                 <item>
                                    <content styleCode="bold">Heart problems.</content> Your healthcare provider should check you for signs or symptoms of heart failure before starting QINLOCK and regularly during treatment with QINLOCK. Heart failure can be serious and can sometimes lead to death. Tell your healthcare provider right away if you have any of the following signs or symptoms during your treatment with QINLOCK:
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>tiredness
</item>
                                 <item>swelling of your stomach-area (abdomen), legs or ankles
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>shortness of breath
</item>
                                 <item>protruding neck veins
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Risk of wound healing problems.</content> Wounds may not heal well during treatment with QINLOCK. Tell your healthcare provider if you plan to have any surgery before or during treatment with QINLOCK.<list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider should tell you when to stop taking QINLOCK before a planned surgery.
</item>
                                       <item>Your healthcare provider should tell you when you may start taking QINLOCK again after surgery.
</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Risk of sensitivity to sunlight (photosensitivity).</content> See <content styleCode="bold">âWhat should I avoid while taking QINLOCK?â</content>
                                    <br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of QINLOCK include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>hair thinning or hair loss
</item>
                                 <item>nausea
</item>
                                 <item>constipation
</item>
                                 <item>diarrhea
</item>
                                 <item>vomiting
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>tiredness
</item>
                                 <item>stomach (abdominal) pain
</item>
                                 <item>muscle pain
</item>
                                 <item>decreased appetite
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">QINLOCK may affect fertility in males which may affect the ability to have children. Talk to your healthcare provider if this is a concern for you.<br/>These are not all the possible side effects of QINLOCK.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store QINLOCK?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store QINLOCK in the original container at room temperature between 68ÂºF to 77ÂºF (20ÂºC to 25ÂºC).
</item>
                                 <item>QINLOCK comes with a desiccant packet in the bottle to protect your medicine from moisture. Do not remove the desiccant packet from the bottle.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Keep QINLOCK and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of QINLOCK.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use QINLOCK for a condition for which it was not prescribed. Do not give QINLOCK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about QINLOCK that is written for health professionals.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in QINLOCK?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> ripretinib<br/>
                              <content styleCode="bold">Inactive ingredients:</content> crospovidone, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and silicon dioxide<br/>
                              <br/>Manufactured for: <content styleCode="bold">Deciphera Pharmaceuticals, LLC</content>, 200 Smith Street, Waltham, MA 02451<br/>QINLOCK is a trademark of Deciphera, LLC. All other trademarks referenced herein are the property of their respective owners.<br/>For more information, call 1-888-724-3274 or go to www.QINLOCK.com
</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20231031"/>
            </section>
         </component>
         <component>
            <section ID="s69">
               <id root="96f4b6e7-c279-45d1-92aa-93fb482b4317"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel - 90 Tablet Carton Label</content>
                  </paragraph>
                  <paragraph>NDC: 73207-101-30 <content styleCode="bold">Rx only
</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">QINLOCKâ¢</content>
                  </paragraph>
                  <paragraph>(ripretinib) tablets
</paragraph>
                  <paragraph>50 mg
</paragraph>
                  <paragraph>Dispense the enclosed Patient<br/>Information Leaflet to each patient.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">90</content>
                  </paragraph>
                  <paragraph>TABLETS
</paragraph>
                  <renderMultiMedia ID="f04" referencedObject="mm04"/>
               </text>
               <effectiveTime value="20231031"/>
               <component>
                  <observationMedia ID="mm04">
                     <text>Principal Display Panel - 90 Tablet Carton Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qin00-0005-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>